LU91072I2 - Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA - Google Patents

Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA

Info

Publication number
LU91072I2
LU91072I2 LU91072C LU91072C LU91072I2 LU 91072 I2 LU91072 I2 LU 91072I2 LU 91072 C LU91072 C LU 91072C LU 91072 C LU91072 C LU 91072C LU 91072 I2 LU91072 I2 LU 91072I2
Authority
LU
Luxembourg
Prior art keywords
inspra
eplerenone
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
LU91072C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU91072I2 publication Critical patent/LU91072I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/008—Ketals at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/007—3 membered carbocyclic rings in position 6-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LU91072C 1983-04-13 1984-04-10 Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA LU91072I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (1)

Publication Number Publication Date
LU91072I2 true LU91072I2 (fr) 2004-04-07

Family

ID=4223123

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91072C LU91072I2 (fr) 1983-04-13 1984-04-10 Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA

Country Status (23)

Country Link
US (1) US4559332A (fr)
EP (1) EP0122232B1 (fr)
JP (1) JPS59231100A (fr)
AR (4) AR241918A1 (fr)
AT (1) ATE39256T1 (fr)
AU (1) AU565017B2 (fr)
CA (1) CA1220781A (fr)
DD (2) DD233375A5 (fr)
DE (2) DE3475622D1 (fr)
DK (1) DK163988C (fr)
ES (4) ES531517A0 (fr)
FI (1) FI77669C (fr)
GR (1) GR81834B (fr)
HU (1) HU191406B (fr)
IE (1) IE57541B1 (fr)
IL (1) IL71504A (fr)
LU (1) LU91072I2 (fr)
NL (1) NL300144I2 (fr)
NO (1) NO159800C (fr)
NZ (1) NZ207826A (fr)
PH (1) PH19997A (fr)
PT (1) PT78413B (fr)
ZA (1) ZA842710B (fr)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
DE69129193T2 (de) * 1991-01-29 1998-07-30 Shionogi Seiyaku K K Trading U Triterpenderivat
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
WO1996040255A2 (fr) * 1995-06-07 1996-12-19 G.D. Searle & Co. Procede de traitement de la fibrose cardiaque par une combinaison therapeutique d'un antagoniste de l'angiotensine ii et d'un antagoniste de l'aldosterone epoxy-steroide
DE69617235T2 (de) * 1995-06-07 2002-07-25 G.D. Searle & Co., Chicago Epoxysteroide aldosteronantagonist und angiotensin ii rezeptor antagonist kombinationstherapie zur behandlung von congestivem herzversagen
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
EP1170299A3 (fr) * 1995-12-11 2004-11-10 G.D. Searle & Co. Produits intermédiares pour la production des stéroides 9,11-époxy et un procédé pour leur production
ATE365171T1 (de) * 1995-12-11 2007-07-15 Searle Llc Verfahren zur herstellung einer epoxyverbindung
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
EP1148061B1 (fr) * 1996-12-11 2007-10-17 G.D. Searle LLC. Procédé d'époxydation
ATE375992T1 (de) * 1996-12-11 2007-11-15 Searle Llc Epoxidierungsverfahren
CA2298453A1 (fr) * 1998-05-29 1999-12-09 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'assaisonnements liquides ayant la saveur de legumes marines dans une pate de son de riz salee
HUP0104249A3 (en) * 1998-11-06 2002-06-28 G D Searle & Co Chicago Pharmaceutical composition for combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
EP1140187B1 (fr) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinaisons d'un inhibiteur d'ibat et d'un inhibiteur de mtp utilisees dans le cadre de troubles cardio-vasculaires
EA009466B1 (ru) 1998-12-23 2007-12-28 Джи.Ди. Сирл Ллс Ингибитор белка, переносящего эфир холестерила
JP2002533414A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
DE69907960T2 (de) * 1998-12-23 2004-02-26 G.D. Searle Llc, Chicago Kombinationen von ileumgallensäuretransports inhibitoren und fibronsäure derivaten für kardiovaskuläre indikationen
ES2200587T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares.
WO2000038721A1 (fr) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinaisons d'inhibiteurs de la proteine de transfert du cholesteryle-ester et de derives de l'acide nicotinique utilisees dans le cadre de troubles cardio-vasculaires
US6569905B1 (en) 1998-12-23 2003-05-27 G.D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
AU2041101A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Eplerenone crystalline form
WO2001042272A2 (fr) * 1999-12-08 2001-06-14 Pharmacia Corporation Forme cristalline d'eplerenone possedant une vitesse de dissolution accrue
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
EP1505072A3 (fr) * 1999-12-08 2006-06-21 Pharmacia Corporation Forme cristalline d'eplerenone possédant une vitesse de dissolution accrue
EP1527782A1 (fr) * 1999-12-08 2005-05-04 Pharmacia Corporation Compositions nanoparticulaires d'eplérenone
WO2001068096A2 (fr) * 2000-03-10 2001-09-20 Pharmacia Corporation Polytherapie pour la prophylaxie et le traitement d'etats et de troubles hyperlipidemiques
EP1286984A2 (fr) 2000-03-10 2003-03-05 Pharmacia Corporation Procede de preparation de tetrahydrobenzothiepines
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
ATE330633T1 (de) * 2000-07-27 2006-07-15 Pharmacia Corp Epoxy-steroidaler aldosteronantagonist und beta- adrenergischer antagonist-kombinationstherapie zur behandlung von kongestivem herzversagen
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
DE60114027T2 (de) * 2000-08-28 2006-07-13 Pharmacia Corp. Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
MX245674B (es) * 2000-10-30 2007-05-07 Pharmacia Corp 11 alfa hidroxilasa y oxidorreductasa de aspergillus ochraceus.
KR20030057549A (ko) * 2000-11-09 2003-07-04 아스트라제네카 아베 블록 공중합체를 포함하는 경구용 약학 조성물
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US6740663B2 (en) * 2001-11-02 2004-05-25 G.D. Searle, Llc Mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
JP2005516914A (ja) 2001-12-12 2005-06-09 ファルマシア・コーポレーション エポキシ−ステロイド系アルドステロン受容体アンタゴニストで眼病を治療する方法
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
KR20040107481A (ko) * 2002-03-18 2004-12-20 파마시아 코포레이션 알도스테론 수용체 길항물질 및 담즙산 격리제의 혼합물
WO2003080068A1 (fr) * 2002-03-18 2003-10-02 Pharmacia Corporation Combinaison d'antagoniste de recepteur d'aldosterone et d'acide nicotinique ou d'un derive d'acide nicotinique
JP2005520856A (ja) * 2002-03-20 2005-07-14 ファルマシア コーポレーション 貯蔵時に安定なエプレレノン製剤
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
SI1487859T1 (sl) * 2002-03-22 2008-10-31 Pharmacia & Upjohn Co Llc Postopek priprave eplerenona
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
MXPA05001857A (es) * 2002-08-16 2005-06-03 Upjohn Co Intermedios esteroideos de 5-androsten-38-ol y procedimientos para su preparacion.
PL376919A1 (pl) * 2002-11-06 2006-01-09 Pharmacia & Upjohn Company Llc Sposoby wytwarzania 7-karboksy-podstawionych steroidów
KR100667123B1 (ko) * 2002-11-07 2007-01-12 파마시아 앤드 업존 캄파니 엘엘씨 Ｃ-7 치환된 5-안드로스텐의 제조 방법
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
US20040266743A1 (en) * 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
BRPI0509057A (pt) * 2004-03-22 2007-08-21 Pharmacia & Upjohn Co Llc processo aperfeiçoado para a preparação de 9,11 epóxi esteróides
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾－4－烯－7，21－二甲酸，9，11－环氧－17－羟基－3－氧代，γ－内酯，甲酯，(7α,11α,17α)－的制备方法
WO2007025780A2 (fr) * 2005-09-02 2007-03-08 Recordati Ireland Limited Antagonistes des recepteurs de l'aldosterone
EP1842543A1 (fr) 2006-04-05 2007-10-10 Speedel Pharma AG Composition pharmaceutique comprennant un inhibiteur de l'aldosteron synthase et un antagoniste de recepteur mineralcorticoide
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
JP2010513325A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬組成物
CA2582496A1 (fr) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Procede ameliore permettant la preparation et la purification de l'eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
WO2011097571A2 (fr) * 2010-02-08 2011-08-11 Prairie Pharmaceuticals, Llc Procédé pour l'utilisation de progestogène comme sensibilisateur aux glucocorticoïdes
WO2011141456A1 (fr) 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pour le traitement de l'accumulation de fluides dans et/ou sous la rétine
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012107513A1 (fr) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Procédé d'obtention de la drospirénone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
ES2699923T3 (es) 2014-10-17 2019-02-13 Ind Chimica Srl Proceso para la preparación de 7alfa-(metoxicarbonil)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactona, un intermedio útil para la síntesis de moléculas con actividad farmacológica
WO2017055248A1 (fr) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques pour le traitement d'une insuffisance cardiaque
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
WO2018019843A1 (fr) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur des minéralocorticoïdes pour le traitement de l'arthrose
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP4395785A1 (fr) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Méthodes de traitement de la rosacée oculaire

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
FI77669B (fi) 1988-12-30
DD251144A5 (de) 1987-11-04
ATE39256T1 (de) 1988-12-15
AR241918A1 (es) 1993-01-29
GR81834B (fr) 1984-12-12
DD233375A5 (de) 1986-02-26
HU191406B (en) 1987-02-27
DK163988B (da) 1992-04-27
FI841400A0 (fi) 1984-04-09
ES544768A0 (es) 1987-05-01
DE122004000012I1 (de) 2012-05-16
ZA842710B (en) 1984-11-28
JPS59231100A (ja) 1984-12-25
CA1220781A (fr) 1987-04-21
IL71504A (en) 1987-07-31
DE122004000012I2 (de) 2006-06-08
ES8705461A1 (es) 1987-05-01
AR242221A1 (es) 1993-03-31
AU565017B2 (en) 1987-09-03
ES8602846A1 (es) 1985-12-01
NL300144I1 (nl) 2004-06-01
PT78413A (en) 1984-05-01
DK163988C (da) 1992-09-21
FI77669C (fi) 1989-04-10
DK189484D0 (da) 1984-04-12
JPH0212479B2 (fr) 1990-03-20
AR242222A1 (es) 1993-03-31
ES544770A0 (es) 1987-05-01
IE840906L (en) 1984-10-13
NO159800B (no) 1988-10-31
PH19997A (en) 1986-08-28
PT78413B (en) 1986-08-22
IL71504A0 (en) 1984-07-31
NO841465L (no) 1984-10-15
ES544769A0 (es) 1987-05-01
FI841400A (fi) 1984-10-14
NO159800C (no) 1989-02-08
EP0122232B1 (fr) 1988-12-14
ES8705460A1 (es) 1987-05-01
US4559332A (en) 1985-12-17
ES531517A0 (es) 1985-12-01
DK189484A (da) 1984-10-14
ES8705459A1 (es) 1987-05-01
NZ207826A (en) 1986-07-11
DE3475622D1 (en) 1989-01-19
NL300144I2 (nl) 2004-06-01
AR242223A1 (es) 1993-03-31
AU2685384A (en) 1984-10-18
EP0122232A1 (fr) 1984-10-17
IE57541B1 (en) 1992-10-07

Similar Documents

Publication Publication Date Title
LU91072I2 (fr) Eplerenone et ses sels pharmaceutiquement acceptables - INSPRA
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
DE3464100D1 (en) Electric-cable structure and its application
IT1205010B (it) Tetraidronaftalin-derivati e indan-derivati
ES542657A0 (es) Perfeccionamientos en los aparatos de fermentacion y proce- dimiento de fermentacion correspondiente
DK41484D0 (da) Beta-phenethanolaminer og deres anvendelse
DK49588D0 (da) Taetnings- og afstrygningsindretning
DK551187D0 (da) Terapeutisk praeparat og dettes fremstilling
DK412787A (da) Medicinsk-kirurgisk pose og dennes fremstilling
DK254488D0 (da) Azaindol- og indolizinderivater
DK210689D0 (da) Steroidderivater
DK553782A (da) Cyclohexyl- og phenylsubstituerede enkephaliner og deres fremstilling
DK413187A (da) Semicarbazoner og thiosemicarbazoner
DK488185D0 (da) N6-benzopyrano- og benzothiopyranoadenosiner
PT89072A (pt) Estojo estanque e impermeavel
DK422984D0 (da) Aminocyklopentaner og farmaceutiske praeparater deraf
DK501989D0 (da) Mikrobiocidt praeparat og dettes fremstilling
DK90591D0 (da) Beskyttelsesramme
DK162607C (da) Azopigmentpraeparater og deres anvendelse
DE3475192D1 (de) Pyrrolizidinones and indolizidones
FR2633963B1 (fr) Sas d'isolation adaptable et amovible
ES1004213Y (es) Nuevos nichos e hipogeos
SE8304181D0 (sv) Energiforfaranden och -anordningar
DK428987D0 (da) En fallelaas
SE8504463D0 (sv) Dosier- und appliziervorrichtung